Halting GLP-1 medications like Ozempic, Wegovy, Mounjaro or Zepbound rapidly erodes their heart health benefits, according to a Washington University School of Medicine study.
Researchers tracked over 333,000 U.S. veterans with type 2 diabetes for three years. Continuous GLP-1 use reduced cardiovascular risk by 18%. But stopping reversed gains quickly: six months off raised risk by 4%, one year by 14%, two years by 22%.
"Protection that takes years to accumulate can vanish in a few months," said lead researcher Dr. Ziad Al-Aly.
Restarting the drugs restored only partial protection - a 12% risk reduction versus 18% with uninterrupted use. "Discontinuation leaves a lasting scar," Al-Aly warned.
Cardiologist Dr. Bradley Serwer emphasized these drugs must be part of long-term care, paired with diet and exercise. Stopping triggers silent metabolic reversal - rising inflammation, blood pressure, cholesterol and insulin resistance - potentially culminating in heart attack or stroke.
The study, published in BMJ Medicine, used observational data from mostly older male veterans. While causation isn’t proven, researchers applied rigorous trial emulation methods.
Experts urge patients to consult physicians before discontinuing treatment. GLP-1s are not quick fixes - they’re chronic disease therapies requiring sustained commitment.